N. Ghilezan - Concepedia

Author

N. Ghilezan

Institute of Oncology Prof. Dr. Ion Chiricuta

Also Known As

N Ghilezan, N. Ghilezan, N. ghilezan, Nicolae Ghilezan

Publications

692

Citations

H-Index

Concepts

All Affiliations

Institute of Oncology Prof. Dr. Ion Chiricuta

About

N. Ghilezan is an author at Institute of Oncology Prof. Dr. Ion Chiricuta specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	519
2	Health Sciences	2	2	80
3	Public Health	1	1	27
4	Obstetrics	1	1	27
5	Pharmacology	1	1	79

N. Ghilezan

Publications

639

Citations

H-Index

Page 1

	Year	Citations
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial Thomas Brodowicz, Maciej Krzakowski, Matjaž Zwitter, Lung Cancer MedicineCancer ManagementPhase Iii TrialMaintenance GemcitabineBronchial Neoplasm	2006	322
Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer G Brufman, E Colajori, N. Ghilezan, Annals of Oncology Metastatic Breast CancerOncologyBreast OncologyMedicineCancer Management	1997	79
Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial George Plataniotis, M.A. Theofanopoulou, Anna Kalogera‐Fountzila, International Journal of Radiation OncologyBiologyPhysics Adaptive RadiotherapyTumor VolumetryRadiation TherapyMedical ImagingMedicine	2004	70
Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial Christoph Zielinski, S. Beslija, Zrinka Mršić-Krmpotić, Journal of Clinical Oncology	2005	63
Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study. E. Ciuleanu, A Irimie, Tudor–Eliade Ciuleanu, PubMed	2008	40
Radiotherapy versus Concurrent 5-Day Cisplatin and Radiotherapy in Locally Advanced Cervical Carcinoma Viorica Nagy, Ovidiu Coza, Claudia Ordeanu, Strahlentherapie und Onkologie Adaptive RadiotherapyCervical Cancer ManagementCervical CancerRadiation TherapyMedicine	2009	27
Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study. Tudor–Eliade Ciuleanu, George Fountzilas, E. Ciuleanu, PubMed	2012	17
O-88 Gemcitabine and cisplatin (GC) +/-subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG) Maciel Krzakowski, M. Wenczl, Thomas Brodowicz, Lung Cancer OncologySingle-agent GemcitabineMetronomic TherapyRandomized TrialCancer Treatment	2003	11
A phase III trial of taxotere and doxorubicin (AT) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: an interim analysis K. Bouzid, J. Vinholes, Fernando Palacios Salas, European Journal of Cancer Interim AnalysisAdvanced Breast CancerBreast OncologyMedicinePhase Iii Trial	2001	10

Page 1